Everest Organics Ltd
EVERESTOEverest Organics Ltd
EVERESTO
Price Chart
Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| -15.83 | 2.07 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 51.27 | 6.55 | 0.51% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Everest Organics Limited is a pharmaceutical company engaged in the business of bulk drugs, intermediates and active pharmaceutical ingredients (APIs).
Peers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Torrent Pharmaceuticals Ltd
Dr Reddy's Laboratories Ltd
Mankind Pharma Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 99.85 | 107.87 | 112.87 | 156.39 | 168.66 | 182.63 | 202.26 | 189.98 | 198.13 | 188.01 | ||||||||||
Raw Materials | 61.72 | 71.32 | 72.98 | 97.00 | 103.52 | 117.13 | 141.72 | 126.31 | 124.64 | 182.21 | ||||||||||
| Power & Fuel Cost | 7.42 | 9.54 | 10.34 | 10.81 | 11.85 | 12.36 | 14.70 | 18.88 | 15.40 | |||||||||||
| Employee Cost | 7.22 | 8.74 | 9.34 | 11.64 | 13.30 | 15.26 | 16.33 | 16.30 | 18.80 | |||||||||||
| Selling & Administrative Expenses | 5.02 | 5.45 | 5.54 | 6.33 | 7.34 | 7.65 | 8.66 | 9.75 | 10.52 | |||||||||||
| Operating & Other expenses | 12.91 | 5.84 | 6.89 | 12.24 | 11.92 | 6.32 | 12.21 | 10.88 | 16.89 | |||||||||||
EBITDA | 5.56 | 6.98 | 7.78 | 18.37 | 20.73 | 23.91 | 8.64 | 7.86 | 11.88 | 5.80 | ||||||||||
| Depreciation/Amortization | 2.73 | 2.45 | 2.68 | 2.84 | 3.21 | 3.37 | 3.80 | 4.47 | 5.80 | 5.97 | ||||||||||
| PBIT | 2.83 | 4.53 | 5.10 | 15.53 | 17.52 | 20.54 | 4.84 | 3.39 | 6.08 | -0.17 | ||||||||||
| Interest & Other Items | 2.60 | 2.76 | 2.74 | 3.21 | 3.43 | 3.26 | 3.10 | 3.31 | 5.47 | 5.47 | ||||||||||
| PBT | 0.23 | 1.77 | 2.36 | 12.32 | 14.09 | 17.28 | 1.74 | 0.08 | 0.61 | -5.64 | ||||||||||
| Taxes & Other Items | 0.04 | 0.43 | 0.65 | 4.82 | 3.20 | 3.56 | 0.60 | 0.28 | 0.47 | 0.35 | ||||||||||
| Net Income | 0.19 | 1.34 | 1.71 | 7.50 | 10.89 | 13.72 | 1.14 | -0.20 | 0.14 | -5.99 | ||||||||||
| EPS | 0.30 | 2.37 | 2.14 | 9.38 | 13.61 | 17.15 | 1.42 | -0.25 | 0.17 | -7.49 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 1.00 | 1.00 | 1.50 | 0.50 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.11 | 0.07 | 0.09 | 0.35 | 0.00 | 0.00 | 0.00 |
Company Updates
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Everest Organics Ltd | 677.43 | 2.07 | — |
| Sun Pharmaceutical Industries Ltd | 45.34 | 6.47 | 0.75% |
| Cipla Ltd | 31.21 | 4.80 | 0.82% |
| Torrent Pharmaceuticals Ltd | 65.38 | 15.80 | 0.88% |
Price Comparison
Compare EVERESTO with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateSep 15, 2022
Dividend/Share
₹0.50
Ex DateEx Date
Sep 15, 2022
Cash Dividend
Ex DateEx DateSep 8, 2021
Dividend/Share
₹1.00
Ex DateEx Date
Sep 8, 2021
Cash Dividend
Ex DateEx DateFeb 17, 2021
Dividend/Share
₹0.50
Ex DateEx Date
Feb 17, 2021
Cash Dividend
Ex DateEx DateSep 1, 2020
Dividend/Share
₹1.00
Ex DateEx Date
Sep 1, 2020
Cash Dividend
Ex DateEx DateSep 3, 2019
Dividend/Share
₹1.00
Ex DateEx Date
Sep 3, 2019
Everest Organics announced that the Annual General Meeting (AGM) of the company will be held on 27 September 2024.Powered by Capital Market - Live
Everest Organics announced that the Annual General Meeting (AGM) of the company will be held on 27 September 2024.Powered by Capital Market - Live
Net loss of Everest Organics reported to Rs 6.09 crore in the quarter ended June 2024 as against net profit of Rs 0.04 crore during the previous quarter ended June 2023. Sales declined 23.95% to Rs 32.45 crore in the quarter ended June 2024 as against Rs 42.67 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales32.4542.67 -24 OPM %-11.285.91 - PBDT-4.621.45 PL PBT-6.090.16 PL NP-6.090.04 PL Powered by Capital Market - Live
Everest Organics will hold a meeting of the Board of Directors of the Company on 13 August 2024.Powered by Capital Market - Live
Everest Organics reports standalone net loss of Rs 1.34 crore in the September 2021 quarter
COVID-19: Everest Organics starts making ingredient for Merck’s molnupiravir drug
India’s Everest Organics starts making ingredient for Merck’s Covid pill
India’s Everest Organics starts making ingredient for Merck’s COVID-19 pill
Everest Organics ends 15% higher on development of Molnupiravir, a new API to treat Covid-19
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 4.85%, vs industry avg of 9.03%
Decreasing Market Share
Over the last 5 years, market share decreased from 0.07% to 0.05%
Lower than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of -54.9%, vs industry avg of 15.28%